These Cholesterol-Reducers May Save Lives. So Why Aren’t Heart Patients Getting Them?

Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices.
By GINA KOLATA from NYT Health https://ift.tt/2DOZiTD
via IFTTT
Repatha (Drug), Drugs (Pharmaceuticals), Health Insurance and Managed Care, Cholesterol
Source The New York Times
Làm đẹp Blog 247